LENZ - LENZ Therapeutics Inc.
IEX Last Trade
23.35
1.250 5.353%
Share volume: 71,017
Last Updated: Fri 30 Aug 2024 09:59:16 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$22.10
1.25
5.66%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.96%
1 Month
-6.81%
3 Months
50.81%
6 Months
50.68%
1 Year
117.72%
2 Year
47.09%
Key data
Stock price
$23.35
DAY RANGE
N/A - N/A
52 WEEK RANGE
$9.51 - $25.77
52 WEEK CHANGE
$1.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO:
Region: US
Website: graphitebio.com
Employees: 119
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: graphitebio.com
Employees: 119
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives
Recent news